Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLC

Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer Eligible patients had KRAS G12C mutations confirmed by histologic or blood-based testing, an ECOG performance status of 0 or 1, and measurable disease...

Dr Negrao on Olomorasib Plus Chemoimmunotherapy in KRAS G12C–Mutant NSCLC

Marcelo V. Negrao, MD, discusses updated efficacy and safety data for first-line olomorasib plus chemoimmunotherapy in KRAS G12C–mutant NSCLC At the 2026 ESMO Congress, Negrao presented updated data from 77 patients with advanced KRAS G12C–mutant non–small cell lung cancer (NSCLC)...

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC Ferdinandos Skoulidis, MD, PhD, MRCP, discusses survival and safety data for divarasib vs sotorasib or adagrasib in KRAS G12C–mutated NSCLC. “Most importantly, in my opinion, the Krascendo 1...

New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC

Credit: Mohammed Haneefa Nizamudeen/Getty Images The next-generation, oral KRAS G12C inhibitor divarasib significantly reduces the risk for disease progression or death compared with existing KRAS-targeted treatments in patients with previously treated KRAS G12C-mutated advanced or metastatic non-small-cell lung cancer (NSCLC),...